Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Vietnam Veteran Discusses Agent Orange Exposure and Bladder Cancer

July 29th 2021

In this episode of the “CURE® Talks Cancer” podcast, a cancer survivor who served in the Vietnam War shares the story of his Agent Orange exposure and bladder cancer.

Continuing to Smoke After Bladder Cancer Diagnosis Increases Recurrence Risk

July 20th 2021

Smoking cigarettes could lead to a four-fold increased risk of recurrence in patients with a previous diagnosis of non-muscle invasive bladder cancer.

Glycemic Index, But Not Glycemic Load or Carb Intake, May Increase Bladder Cancer Risk

July 19th 2021

An analysis showed that glycemic index – but not glycemic load or total carbohydrate intake – significantly increased the risk of developing bladder cancer.

FDA Grants Regular Approval to Padcev for Pretreated Metastatic or Advanced Bladder Cancer

July 9th 2021

Approximately 18 months after granting Padcev an accelerated approval, the Food and Drug Administration granted a regular approval to the treatment for certain previously treated patients with locally advanced or metastatic urothelial carcinoma.

Patients Should Ask Their Providers About Clinical Trial Results

July 7th 2021

Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.

VA Adds Bladder Cancer as Potential Effect of Agent Orange Exposure

July 7th 2021

Agent Orange exposure impacted millions of U.S. military personnel during the Vietnam War. The chemical may have led to bladder cancer diagnoses later in life.

Trimodality Treatment Including Keytruda May Provide Non-Surgical Treatment Option for Subset of Bladder Cancer

July 4th 2021

Keytruda plus gemcitabine and higher doses of radiotherapy showed promising efficacy and safety results in patients with muscle-invasive bladder cancer.

ctDNA Positivity May Improve Post-Surgical Immunotherapy Response in Bladder Cancer

June 30th 2021

Patients who tested positive for the biomarker circulating tumor DNA (ctDNA) had improved disease-free and overall survival after receiving Tecentriq.

Bladder-Saving Treatment Regimen Shows Promise in Patients with Bladder Cancer

June 10th 2021

A combination of treatment with bladder-saving surgical resection, Opdivo and chemotherapy yielded positive results in patients with muscle-invasive bladder cancer.

Front-line Bavencio Maintenance Improves Survival Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Bladder Cancer

June 7th 2021

The study’s lead author noted that the data support giving patients with advanced bladder cancer chemotherapy to get control of the disease and then maintaining that control with maintenance Bavencio.

YouTube May Provide Misleading Information About Bladder Cancer

May 25th 2021

Some of the most popular YouTube videos about bladder cancer are of poor quality, spread misinformation and have commercial bias.

The Cancer Diagnosis That Seemed to Make Little Sense

May 24th 2021

A retirement counselor with bladder cancer shares the story of his diagnosis and his thoughts on treatment.

News and Updates for Bladder Cancer Awareness Month

May 13th 2021

A roundup of some of CURE®’s latest news and updates for patients with bladder cancer in honor of Bladder Cancer Awareness Month this May.

FDA Panel Votes in Favor of Upholding Tecentriq’s Indication in First-Line Treatment of Bladder Cancer

May 5th 2021

FDA committee members recently voted in favor of upholding Tecentriq’s accelerated approval indication for the first-line treatment of certain adults with locally advanced or metastatic urothelial carcinoma who are ineligible for standard chemotherapy.

A Cancer Research Writer Turns His Pain Into Hope For Others

April 22nd 2021

In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.

Almost 5% of Patients Undergo Incomplete Procedure to Remove Kidney and Nearby Tissue for Upper Tract Urothelial Carcinoma

April 13th 2021

Several factors were associated with patients undergoing radical nephrectomy compared with radical nephroureterectomy including Black race, large tumors, advanced tumor stage and high-grade tumors.

FDA Grants Accelerated Approval to Trodelvy for Advanced Bladder Cancer

April 13th 2021

Trodelvy has received accelerated approval from the FDA for the treatment of patients with advanced urothelial cancer.

Adjusted-Dose Combination Therapy May Address Needs of Patients with Urothelial Carcinoma Unable to Tolerate Cisplatin Treatment

April 12th 2021

Adjusting the dose of cisplatin, when added to regular doses of Abraxane and gemcitabine, led to similar survival rates when treating patients with advanced/metastatic urothelial carcinoma, which may help to address issues commonly seen with patients who cannot tolerate cisplatin such as renal dysfunction.

Tecentriq’s Indication for Previously Treated Metastatic Bladder Cancer Pulled by FDA, Manufacturer

March 9th 2021

If patients were receiving Tecentriq for prior platinum-based treated metastatic urothelial carcinoma, they should discuss next best steps with their health care providers.

Why It’s Important to ‘Live Well With Your Cancer’

March 4th 2021

While it is important to educate oneself after receiving a diagnosis of cancer, it’s also critical to know when to step away and find a balance between cancer and life, according to Diane Zipursky-Quale.

As Cases of Bladder Cancer Rise, One Organization Can Help Educate and Connect Patients

February 24th 2021

To discuss the projected rise in bladder cancer cases in 2021, CURE® spoke with Bladder Cancer Advocacy Network (BCAN) co-founder Diane Zipursky-Quale, who offered some insight on why the numbers continue to rise, and provides some hope in the form of educational programs offered by her organization.

Padcev Continues to Show Promise in Patients with Previously Treated Bladder Cancer

February 15th 2021

Treatment with Padcev, compared to chemotherapy, continues to show better results in patients with advanced urothelial carcinoma who had previously received certain therapies.

Bladder Cancer Matters Podcast Part 2: Why Bladder Cancer Patients May Need an Oncology Social Worker with Dr. Heather Goltz

February 15th 2021

In Episode 2 of the “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Heather Honoré Goltz in Part 2 of a two-part episode.

Bladder Cancer Matters Podcast: Should Bladder Cancer Patients Work with an Oncology Social Worker?

February 14th 2021

The Bladder Cancer Advocacy Network's new podcast by, for, and about the bladder cancer community, "Bladder Cancer Matters," has a new episode available.

BCAN's First "Bladder Cancer Matters" Podcast is Now Available

February 2nd 2021

In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.

Announcing BCAN’s 2021 Young Investigator Award

January 30th 2021

The Bladder Cancer Advocacy Network (BCAN) announced that it is accepting applications for our 2021 Young Investigator Awards (YIAs).

BCAN Announces 2021 Bladder Cancer Research Innovation Award

January 26th 2021

BCAN is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer.

BCAN Ranked as a Top Charity with a 4-Star Ranking for Seventh Consecutive Year

January 18th 2021

The Bladder Cancer Advocacy Network’s (BCAN’s) strong financial health and commitment to accountability and transparency have earned it a seventh consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This award puts BCAN in the top seven percent of all charities.

BCAN Applauds Bill to Provide Long-Overdue Help to Veteran Bladder Cancer Patients

January 11th 2021

The Bladder Cancer Advocacy Network (BCAN) is pleased that the U.S. Senate voted overwhelmingly to approve the National Defense Authorization Act (NDAA) which contains a critical provision that will help veterans who were exposed to Agent Orange and later developed bladder cancer.

Higher Tumor Classification and Grade for Nonmuscle-Invasive Bladder Cancer May Increase Recurrence and Progression Risk Up to Five Years

December 1st 2020

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

NEXT PAGE
PREVIOUS PAGE